Efficacy of Generic Bortezomib Used as a Part of CyBorD Regimen to Achieve Complete Response in Multiple Myeloma

Innovative Journal of Medical and Health Science
doi 10.15520/ijmhs.v9i1.2431
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Innovative Journal

Related search

Efficacy and Safety of Reduced-Intensity Induction Therapy With a Bortezomib-Based Regimen in Elderly Patients With Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2012English

Attainment of a Stringent Complete Response in Multiple Myeloma With Thalidomide Monotherapy

Internal Medicine
Internal MedicineMedicine
2012English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Intravenous (IV) Bortezomib Infusion After Non-Response to Subcutaneous Bortezomib Administration Can Induce Transitory Responses in Multiple Myeloma Patients: Are Some Patients More Sensitive to IV Bortezomib?

British Journal of Haematology
Hematology
2016English

Efficacy of Subcutaneous Bortezomib in the Management of Patients With Multiple Myeloma or Relapsed Mantle Cell Lymphoma

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2014English

Bortezomib: The Evidence of Its Clinical Impact in Multiple Myeloma

Core Evidence
MedicineReviewsReferencesPharmacology
2006English

Intracellular Glutathione Determines Bortezomib Cytotoxicity in Multiple Myeloma Cells

Blood Cancer Journal
OncologyHematology
2016English

Bortezomib Induces Heme Oxygenase-1 Expression in Multiple Myeloma

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2012English

Blood Distribution of Bortezomib and Its Kinetics in Multiple Myeloma Patients

Clinical Biochemistry
MedicineClinical Biochemistry
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy